Taken together, FXR signaling appears to be critical in mediating these effects, emphasizing the potential of puerarin as a therapeutic agent in ameliorating hepatic dysfunction associated with obesity-induced alterations in bile acid metabolism. The gene discussed is NR1H4; the disease is obesity disorder.